Hikal Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Hikal Ltd is ₹ 183.95 as of 12 Jun 15:30 . The P/E Ratio of Hikal Ltd changed from 13.3 on March 2021 to 54.4 on March 2025 . This represents a CAGR of 32.54% over 5 yearsThe P/E Ratio of Procter & Gamble Health Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Hikal Ltd changed from ₹ 1769 crore on March 2021 to ₹ 4933 crore on March 2025 . This represents a CAGR of 22.76% over 5 yearsThe Market Cap of Procter & Gamble Health Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Hikal Ltd for the Mar '26 is ₹ 526 crore as compare to the Dec '25 revenue of ₹ 497.1 crore. This represent the growth of 5.81% The revenue of Procter & Gamble Health Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Hikal Ltd for the Mar '26 is ₹ 64.9 crore as compare to the Dec '25 ebitda of ₹ 47.5 crore. This represent the growth of 36.63% The ebitda of Procter & Gamble Health Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Hikal Ltd changed from ₹ 5.1 crore to ₹ 14.4 crore over 8 quarters. This represents a CAGR of 68.03% The net profit of Procter & Gamble Health Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The dividend payout of Hikal Ltd changed from 10.87 % to 21.32 % over 5 quarters. This represents a CAGR of 71.41% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Hikal Ltd

Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals.
The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India.
It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division.
Within pharmaceutical division, it offer human health and animal health products. Hikal commenced its first project in 1991 at its first greenfield site at M.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Hikal Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Hikal Ltd or Procter & Gamble Health Ltd?

Market cap of Hikal Ltd is 2,268 Cr while Market cap of Procter & Gamble Health Ltd is 10,413 Cr

What are the key factors driving the stock performance of Hikal Ltd and Procter & Gamble Health Ltd?

The stock performance of Hikal Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hikal Ltd and Procter & Gamble Health Ltd?

As of June 14, 2026, the Hikal Ltd stock price is INR ₹183.95. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹6273.55.

How do dividend payouts of Hikal Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Hikal Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.